European Multidisciplinary Conference in Thoracic Oncology

The number of diagnostic and therapeutic options for patients with thoracic malignancies has markedly increased, allowing for an individualized approach based on the clinical situation and molecular characteristics of the tumor. How to best select among these options for the benefit of the patients within an integrative treatment approach will be at the core of the conference.

"The number of diagnostic and therapeutic options for patients with thoracic malignancies has markedly increased, allowing for an individualized approach based on the clinical situation and molecular characteristics of the tumor. How to best select among these options for the benefit of the patients within an integrative treatment approach will be at the core of the conference"

Rolf Stahel, EMCTO 2011 Chair

Despite the fact that chest tumors are difficult to treat, major advances have been made in areas such as the testing of EGFR mutations, the use of targeted therapies in advanced non-small cell lung cancer and the establishment of adjuvant chemotherapy in completely resected NSCLC or prophylactic cranial irradiation in small-cell lung cancer, and improvements in radiotherapy and surgery techniques.

As a multidisciplinary, educational conference, EMCTO will provide an update on recent advances in the prevention, biology, diagnosis, staging and treatment of thoracic malignancies.

Experts of the various disciplines will discuss these advances and provide a multidisciplinary overview and update of the current state-of-the-art management of patients with thoracic malignancies.

The conference full program is available at http://www.esmo.org/events/lung-2011-emcto/program.html

Please contact the EMCTO Press Office immediately at media@esmo.org to book a telephone hook-up, to schedule your remote interviews or register for the event.

All sessions are open to journalists and registration is free to bona fide journalists on presentation of a valid press card and a letter of assignment.

Provided by European Society for Medical Oncology